



**NIH SIREN
Emergency
Trials
Network**

Clinical Coordinating Center
University of Michigan
Lobby H, Suite H3100
24 Frank Lloyd Wright Drive
Ann Arbor, MI 48106
734-232-2142

Clinical Coordinating Center
University of Michigan

William G. Barsan, MD
Robert Silbergleit, MD
Clifton Callaway, MD, PhD
Principal Investigators

Will Meurer, MD, MS
Fred Korley, MD, PhD
Adrienne Haggins, MD, MS

Valerie Stevenson, BAS, CCRP
Administrative Director

Data Coordinating Center
Medical University of South Carolina

Valerie Durkalski, PhD
Sharon Yeatts, PhD
Principal Investigators

National Institutes of Health

Jeremy Brown, MD
*Director, Office of Emergency Care Research
Program Director, NINDS*

Carolina Mendoza-Puccini, MD
Robin Conwit, MD
Scott Janis, PhD
Program Directors NINDS

George Sopko, MD, MPH
Program Director, NHLBI

Michelle Culp, BSN, MPH
Program Director NCATS

Award Hub Contact Principal Investigators

Opeolu Adeoye, MD
University of Cincinnati

Tom Aufderheide, MD
Medical College of Wisconsin

Michelle Biros, MD, MS
University of Minnesota

Clifton Callaway, MD, PhD
University of Pittsburgh

Mohamud Daya, MD, MS
Oregon Health & Science University

Nina Gentile, MD
Temple University

Joshua Goldstein, MD, PhD
Massachusetts General Hospital

Peter Kudenchuk, MD
University of California, San Francisco

Brian O'Neil, MD
Wayne State University

Sidney Starkman, MD
University of California, Los Angeles

David Wright, MD
Emory University

BOOST-3 Protocol Revision: BOOST-3 Study Protocol Version 3

This revision of the BOOST-3 clinical trial protocol does not involve any substantive changes to the research or the safety or experiences of human subjects. Rather this new version is just intended to clarify several items in the protocol about which we have been answering questions and providing additional training since the protocol was initiated. It also corrects some minor mistakes, and numerous typographical, formatting, and grammatical errors that we have accumulated over time. Important clarifications in the eligibility criteria include a more specific description of how to implement the exclusion for poor bilateral pupillary response, and correction of the intended PF ratio threshold for exclusion. Both of these changes in the protocol simply clarify or correct the protocol to reconcile it with, and reinforce, the study team training that has already been used since the start of the trial. Extensive clarifications in the tier treatment descriptions better reflect the wording and descriptions of the clinical interventions as used in practice, but do not actually alter the treatments recommended to be used to respond to ICP or brain tissue hypoxia events.

Ramon Diaz-Arrastia, MD, PhD
BOOST-3 Protocol PI

William Barsan, MD
BOOST-3 Contact PI, SIREN CCC PI

Lori Shutter, MD
BOOST-3 Clinical PI

Sharon Yeatts, PhD
BOOST-3 Biostatistical PI, SIREN DCC PI